Novo Nordisk A/S (NONOF)
| Market Cap | 196.74B |
| Revenue (ttm) | 49.58B |
| Net Income (ttm) | 16.30B |
| Shares Out | n/a |
| EPS (ttm) | 3.67 |
| PE Ratio | 12.07 |
| Forward PE | 11.58 |
| Dividend | 1.66 (3.46%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 753 |
| Average Volume | 162,294 |
| Open | 43.50 |
| Previous Close | 48.00 |
| Day's Range | 43.10 - 45.00 |
| 52-Week Range | 43.10 - 114.00 |
| Beta | 0.35 |
| RSI | 31.79 |
| Earnings Date | Nov 5, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk has a lot of challenges next year and beyond, says Guggenheim's Seamus Fernandez
Seamus Fernandez, Guggenheim biotech analyst, joins 'Power Lunch' to discuss Novo Nordisk's latest earnings results, if there's a clear winner in the GLP-1 space and much more.
Novo Nordisk has a lot of challenges next year and beyond, says Guggenheim's Seamus Fernandez
Seamus Fernandez, Guggenheim biotech analyst, joins 'Power Lunch' to discuss Novo Nordisk's latest earnings results, if there's a clear winner in the GLP-1 space and much more.
Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial
The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Stocks making the biggest moves midday: Novo Nordisk, Inspire Medical, Tesla, Tegna, Oscar Health and more
These are some of the stocks posting the largest midday moves.
Novo Nordisk stumbles against Eli Lilly in GLP-1drug battle. Which stock is the best buy from here?
Eli Lilly's stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its rising valuation.
Weight-Loss Drugs Don’t Appear to Work Against Alzheimer’s
Novo Nordisk reports disappointing results from the first large study of GLP-1 weight-loss drugs and their effect on Alzheimer’s disease.
Citi's Geoff Meacham: Novo misses on Alzheimer's trial, but ‘winners keep winning' in obesity drugs
Geoff Meacham, Citi head of U.S. pharma and biotech research, joins CNBC's 'Money Movers' to discuss his reaction to results from a drug trial Novo Nordisk, outlooks on the stock, and much more.
Novo Nordisk (NVO) Shares Decline by 6.3%
Novo Nordisk (NVO) Shares Decline by 6.3%
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2245657838-21d03c8782cd4c51aa990c55c3461384.jpg)
Top Stock Movers Now: Tesla, Google Parent Alphabet, Carvana, Novo Nordisk, and More
Major U.S. equities indexes climbed Monday afternoon as tech stocks rallied, and as optimism about a rate cut by the Federal Reserve next month grew.
Oversold Conditions For Novo-Nordisk (NVO)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Top pharmaceutical stocks by Quant to focus on as Novo Nordisk slides
Citi's Geoff Meacham: Novo misses on Alzheimer’s trial, but ‘winners keep winning’ in obesity drugs
Geoff Meacham, Citi head of U.S. pharma and biotech research, joins CNBC's 'Money Movers' to discuss his reaction to results from a drug trial Novo Nordisk, outlooks on the stock, and much more.
Novo Nordisk Hits A 10-Year Low - I Think The Market Is Making A Mistake
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2245789734-c165591d54424fd2a6eb9d0ae34ce24c.jpg)
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.
Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
Biogen Inc. (NASDAQ: BIIB) stock traded higher after Novo Nordisk A/S (NYSE: NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-...
Novo Nordisk's Alzheimer's Trials Disappoint, Impacting Stock Performance
Novo Nordisk's Alzheimer's Trials Disappoint, Impacting Stock Performance
Novo Nordisk 'lottery ticket' Alzheimer's trials fail to deliver reward
Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease's progression - were always a long-shot, although they had offered the drugmaker a potential ...
Novo Nordisk (NVO) Shares Drop Amid Market Fluctuations
Novo Nordisk (NVO) Shares Drop Amid Market Fluctuations
Novo Nordisk stock slides as its Alzheimer's drug trials fail
Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to ...
Novo Nordisk Alzheimer’s drug trials fail in blow to weight-loss giant
Novo Nordisk’s closely-watched Alzheimer’s trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday.
Novo Nordisk: Semaglutide's Success In Alzheimer's Was Unlikely
Pharma market shake-up: Bayer jumps, Novo Nordisk sinks 10%
Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention...
US markets today: Wall Street opens higher as rate-cut hopes rise; holiday-shortened week keeps traders cautious
US stocks opened higher on Monday, with the S&P 500, Dow Jones, and Nasdaq all advancing. This positive sentiment is driven by expectations of a December Federal Reserve rate cut, overshadowing a setb...
Ozempic-maker's shares plunge after failed Alzheimer's trial
Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer's disease.